THE RUSSIAN DATA OF INTERNATIONAL ENDORSE REGISTER (EPIDEMIOLOGIC INTERNATIONAL DAY FOR THE EVALUATION OF PATIENTS AT RISK OF VENOUS THROMBOSIS IN ACUTE HOSPITAL CARE SETTING)

Aim. To estimate a risk factor frequency of venous thromboembolism (VTE) in patients urgently hospitalized in hospitals, and also to estimate of patients part having effective prevention of VTE.

Material and methods. ENDORSE (Epidemiologic International Day for the Evaluation of Patients at Risk of Venous Thrombosis in Acute Hospital Care Setting) is the international register. Patients of 40 years and older hospitalised in therapeutic departments as well as patients of 18 years and older hospitalised in surgical departments (358 hospitals in 32 countries) were included in the register. The case history analysis of all patients was performed for estimation of risk VTE and evaluation of preventive therapy quality according to American College of Chest Physicians (ACCP) Recommendation 2004.

Results. Totally 68 183 patients (including 30 827 (45%) surgical patients and 37 356 (55%) therapeutic patients) were enrolled in Global ENDORSE Register. Russian centers enrolled 4 788 patients (including 2 829 (59%) surgical patients and 1 959 (41%) therapeutic patients). Totally 35 329 (51,8%) patients enrolled in Global ENDORSE Register (64,4% of surgical patients (19 842) and 41,5% of therapeutic patients (15 487)) had VTE risks. In Russia 2 188 enrolled patients (45,7%) had VTE risks (52% of surgical patients (1 470) and 36,7% of therapeutic patients (718). Totally 17 732 (50,2%) patients enrolled in Global Register ENDORSE and having VTE risks received VTE preventive therapy according to АССР Recommendations 2004. In Russia 521 (23,8%) patients enrolled in Global ENDORSE Register and having VTE risks received VTE preventive therapy according to АССР Recommendations 2004. It is more than 2 times less in comparison with world level (р<0.001).

Conclusion. There are a lot of patients with VTE risks in hospitals. It is necessary to improve preventive therapy of VTE due to better hospital management and more active use of АССР Recommendations 2004.

1. Schellong S. M., Bounameaux H., Buller H. Venous Thromboembolism. In Editors: Camm A.J., Luscher Th.F., Serruys P. W. The ESC Textbook of Cardiovascular Medicine. Oxford: Blackwell Publishing; 2006. p.1067-1092.

2. Cohen A.T., Alikhan R., Arcelus J.I. et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005;94(4):750-9.

3. Lindblad B., Eriksson A., Bergquist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1968. Br J Surg 1991;78:849-52.

4. Sandler D.A., Martin J.F. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989;82:203-5.

5. Stein P.D., Henry J. W. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995;108:978-81.

6. Seligsohn U., Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222-31.

7. Anderson F. A., Wheeler H.B., Goldberg R.J. et al. A population-based perspective of hospital incidence and case-fatality rates of deep venous thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 1991;151:933-8.

8. Geerts W.H., Heit J.A., Clagett G.P. et al. Prevention of venous thromboembolism. Chest 2001;119:132S-175S.

9. Douketis J.D., Eikelboom J.W., Quinlan D. J. et al. Short-duration porophylaxis against venous thromboembolism after total hip and knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002;162:1465-71.

10. Eriksson B. I., Lassen M. R. The PENTassccharide in Hip-FRActure Surgery Plus (PENTIFRA Plus) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled doubleblind study. Arch Intern Med 2003;163:1337-42.

11. Prevention of fatal pulmonary embolism by low doses of heparin. An International Multicenter Trial. Lancet1975;2:45-51.

12. White R. H., Romano P. S., Zhou H. et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern. Med 1998;158:1525-31.

13. Cipolle M. D., Wojcik R., Seislove E. et al. The role of surveillance duplex scanning in preventing venous thromboembolism in trauma patients. J Trauma 2002;52:453-62.

14. Paiement G.D., Wessinger S. J., Harris W. H. Cost-effectiveness of prophylaxis in total hip replacement. Am J Surg 1991;161:519-24.

15. Clagett G. P., Reisch J. S. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 1988;208:227-40.

16. Collins R., Scrimgeour A., Yusuf S. et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318:1162-73.

17. Koch A., Ziegler S., Breitschwerdt H. et al. Low molecular weigh heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. Thromb Res 2001;102:295-309.

18. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):338S-400S.

19. Alikhan R, Peters F, Wilmott R, Cohen AT. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol. 2004;57(12):1254-7.

20. Bouthier J. The venous thrombotic risk in nоnsurgical patients. Drugs 1996; 52 (suppl. 7): 16-29.

21. Goldhaber S. Z., Savage D.D., Garison R. J. et al. Risk factors for pulmonary embolism: the Framingham Study. Am J Med 1983;74:1023-8.

22. Heit J.A., OFallon W. M., Petterson T. M. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245-8.

23. Oger E., Bressollette L., Nonent M. et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients: the TADEUS Project. Thromb Haemost 2002;88:592-7.

24. Samama M.M., Cohen A.T., Darmon J.Y. et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.

25. Cohen A.T. Venous thromboembolic disease management in of nonsurgical moderate and high-risk patients. Semin Hematol. 2000;37(3 Suppl 5):19-22.

26. Cohen A.T., Wolozinsky M. The significance of distal vein thrombosis and bilateral disease. J Thromb Haemost 2005;3(7):1360-1.

27. Howell M.D., Geraci J.M., Knowlton A.A. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective case-report study. J Clin Epidemiol 2001;54:810-6.

28. Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-20.

29. Tveit D.P., Hypolite I.O., Hsheih P. et al. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 2002;39:1011-7.